1. AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501. (September 2021) Authors: Macaluso, F.S.; Cappello, M.; Busacca, A.; Fries, W.; Viola, A.; Costantino, G.; Magnano, A.; Vinci, E.; Ferracane, C.; Privitera, A.C.; Piccillo, G.; Belluardo, N.; Giangreco, E.; Romano, C.; Citrano, M.; Graziano, F.; Garufi, S.; Bertolami, C.; Ventimiglia, M.; Scrivo, B. Journal: Digestive and liver disease Issue: Volume 53(2021)Supplement 3 Page Start: S162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OC.02.3 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB, ADALIMUMAB, AND GOLIMUMAB IN PATIENTS WITH ULCERATIVE COLITIS: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). (1st October 2020) Authors: Macaluso, F.S.; Ventimiglia, M.; Fries, W.; Viola, A.; Cappello, M.; Scrivo, B.; Magnano, A.; Pluchino, D.; Camilleri, S.; Garufi, S.; Di Mitri, R.; Mocciaro, F.; Magrì, G.; Ferracane, C.; Citrano, M.; Graziano, F.; Bertolami, C.; Renna, S.; Orlando, R.; Rizzuto, G. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 2 Page Start: S9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OC.12.1 SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2. (1st October 2020) Authors: Macaluso, F.S.; Fries, W.; Viola, A.; Centritto, A.; Cappello, M.; Giuffrida, E.; Privitera, A.C.; Piccillo, G.; Magnano, A.; Vinci, E.; Vassallo, R.; Trovatello, A.; Belluardo, N.; Giangreco, E.; Camilleri, S.; Garufi, S.; Bertolami, C.; Ventimiglia, M.; Renna, S.; Orlando, R. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 2 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P.07.1 ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) ARE LESS LIKELY TO PERSIST ON ANTI-TNF THERAPY COMPARED WITH YOUNGER PATIENTS. DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD). (25th March 2019) Authors: Porcari, S.; Fidanza, O.; Alibrandi, A.; Renna, S.; Cappello, M.; Siringo, S.; Privitera, A.C.; Inserra, G.; Mocciaro, F.; Magrì, G.; Carroccio, A.; Belluardo, N.; Bertolami, C.; Garufi, S.; Ventimiglia, M.; Macaluso, F.S.; Viola, A.; Cottone, M.; Orlando, A.; Fries, W. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 2 Page Start: e221 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PC.01.2 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB AND ADALIMUMAB IN CROHN'S DISEASE: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). (1st October 2020) Authors: Macaluso, F.S.; Ventimiglia, M.; Fries, W.; Viola, A.; Sitibondo, A.; Cappello, M.; Scrivo, B.; Busacca, A.; Privitera, A.C.; Camilleri, S.; Garufi, S.; Di Mitri, R.; Mocciaro, F.; Belluardo, N.; Giangreco, E.; Bertolami, C.; Renna, S.; Orlando, R.; Rizzuto, G.; Cottone, M. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 2 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PC.01.3 SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). (September 2021) Authors: Macaluso, F.S.; Giuliano, A.; Fries, W.; Viola, A.; Abbruzzese, A.; Cappello, M.; Giuffrida, E.; Carrozza, L.; Privitera, A.C.; Magnano, A.; Ferracane, C.; Scalisi, G.; Minissale, M.G.; Giangreco, E.; Garufi, S.; Bertolami, C.; Cucinotta, U.; Graziano, F.; Renna, S.; Rizzuto, G. Journal: Digestive and liver disease Issue: Volume 53(2021)Supplement 3 Page Start: S88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. T.06.2 USTEKINUMAB IS A PROMISING OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE. (March 2023) Authors: Macaluso, F.S.; Grova, M.; Mocciaro, F.; Di Mitri, R.; Privitera, A.; Distefano, M.; Vitello, A.; Camilleri, S.; Ferracane, C.; Pluchino, D.; Belluardo, N.; Giangreco, E.; Fries, W.; Viola, A.; Cappello, M.; D'Amato, L.; Bertolami, C.; Ventimiglia, M.; Renna, S.; Casa, A. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 2 Page Start: S159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗